Acrophobia Clinical Trial
Official title:
Virtual Reality and Brain Stimulation, an Experiential Approach
The aim of this study is to assess feasibility, acceptability and efficacy of two VRET (Virtual Reality Exposition Therapy)session associated with either active anodal tDCS or sham tDCS on the ventromedial prefrontal cortex to decrease anxiety related to visual height intolerance
Subjects suffering from visual height intolerance are asked to go in 20 min as height as
possible riding in two elevators of adjacents buildings separated by a board they have to
cross at each stage.
Inclusion visit:
- Confirmation of eligibility criteria
- Written informed consent
- Completion of Acrophobia Questionnaire (AQ), Attitude towards Height Questionnaire
(ATHQ), Height Interpretation Questionnaire (HIQ), Visual Height Intolerance scale(vHI),
State-Trait Anxiety (STAI), Inventory and Clinical Global Impressions (CGI)
- Virtual task (10 minutes): riding in an elevator. At each level,subjects are asked to
rate their Subjective Units Discomfort (SUD scale from 0 to 100).
- Assessment of basal cortisol before beginning of exposure to virtual reality (sampling
saliva through a Salivette®)
- Pulse and blood pressure measurements before and after session
Session 1 (within 1 to 7 days following Inclusion Visit) and session 2 (within 48 hours
following session 1):
- Randomization is made by the tDCS software (double bind).
- Equipment of subject with Vive Headset (virtual reality HTC vive), trackers and (tDCS).
The subject does not see the experimental room.
- Virtual task (20 minutes): the subject has to ride in an elevator up to the next floor,
cross a footbridge between 2 buildings to access the elevator on the other side and be
able to climb to the next floor. At each level, the subject asked to rate their SUD. The
objective is to climb as high as possible.
- The active or sham brain stimulation is applied randomly during the entire virtual task.
- Assessment of basal cortisol before and after exposure to virtual reality
- Pulse and blood pressure measurements before and after session
- After session: debriefing and explication of the subjective experience (30 minutes).
End of study visit:
- Identical to inclusion visit plus :
- acrophobia/visual height
- Completion of Simulator Sickness Questionnaire (SSQ) and Igroup Presence Questionnaire
(IPQ)
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT02584387 -
3D Video Virtual Reality Exposure Therapy Study
|
N/A | |
Not yet recruiting |
NCT06468878 -
Virtual Reality Intervention for Fear of Heights
|
N/A | |
Completed |
NCT04737915 -
Virtual Reality Exposure Versus In Vivo Exposure for Fear of Heights
|
N/A | |
Completed |
NCT04975854 -
Virtual Reality Exposure Therapy for Acrophobia
|
N/A | |
Completed |
NCT04620447 -
Intelligent Virtual Reality Therapy System and Testing Its Clinical Efficacy
|
Phase 1/Phase 2 | |
Completed |
NCT05841329 -
Efficacy of tDCS to Enhance Virtual Reality Exposure Therapy Response in Acrophobia
|
N/A | |
Completed |
NCT05780203 -
CBM in the Context of Exposure for Acrophobia
|
N/A | |
Suspended |
NCT03917433 -
Augmenting Virtual Reality Exposure Therapy for Acrophobia
|
N/A | |
Not yet recruiting |
NCT03893214 -
Single Session Virtual Reality Therapy in Acrophobia - and the Role of Respiration
|
N/A |